Unlock AI-driven, actionable R&D insights for your next breakthrough.

Creatine Phosphate Metabolomics: Comprehensive Analysis Of Energy Metabolism Pathways And Therapeutic Applications

NOV 17, 202649 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Creatine Phosphate Metabolomics represents a specialized field investigating the dynamic interplay between creatine phosphate (CrP), creatine kinase (CK) enzyme systems, and cellular energy homeostasis through advanced metabolomic profiling techniques. This interdisciplinary domain integrates biochemical pathway analysis, high-resolution mass spectrometry, and systems biology approaches to elucidate the role of the CK/CrP system in ATP regeneration, phosphoryl transfer kinetics, and metabolic signaling across tissues with high and fluctuating energy demands—including skeletal muscle, cardiac tissue, brain, retina, and pancreatic β-cells 1 5 6.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Composition And Structural Characteristics Of Creatine Phosphate In Metabolomic Contexts

The creatine phosphate molecule (N-phosphocreatine, CrP) serves as the immediate phosphoryl donor in the reversible reaction catalyzed by creatine kinase: CrP + ADP ⇌ Cr + ATP 5 6. Structurally, CrP comprises a guanidinium moiety covalently bonded to a phosphate group via a high-energy phosphorus-nitrogen (P-N) bond, which exhibits a standard free energy of hydrolysis (ΔG°') of approximately −43.0 kJ/mol under physiological conditions 1 2. This thermodynamic property positions CrP as a critical temporal energy buffer, enabling rapid ATP replenishment during transient metabolic surges 5 6.

Structural Variants And Analogs In Metabolomic Studies

Metabolomic investigations frequently employ creatine phosphate analogs to probe enzyme kinetics and pathway flux:

  • Cyclocreatine phosphate: A planar cyclic analog with enhanced P-N bond stability (ΔG°' hydrolysis ~−38 kJ/mol), exhibiting slower dephosphorylation kinetics compared to native CrP 2 7 8. This analog serves as a substrate for CK both in vitro and in vivo, allowing researchers to dissect rate-limiting steps in energy transfer 5 6.
  • 3-Guanidinopropionic acid (3-GPA): An endogenous metabolite and CK substrate analog that competitively inhibits creatine uptake, used experimentally to induce chronic energy depletion states for metabolomic profiling 5 9.
  • Guanidinoacetate (GAA): The immediate biosynthetic precursor of creatine, catalyzed by guanidinoacetate N-methyltransferase (GAMT). Elevated GAA levels in metabolomic datasets indicate upstream defects in creatine biosynthesis or transporter dysfunction 7 8.

Quantitative metabolomic platforms (LC-MS/MS, GC-MS) routinely measure CrP, Cr, and analogs with detection limits in the low micromolar range (0.5–2 μM in serum; 5–30 mM in tissue extracts) 3 10. Isotope-dilution mass spectrometry using 13C2-creatine or 15N2-creatine internal standards ensures accurate quantification across biological matrices 3 12.

Creatine Kinase Isoenzyme Systems And Their Metabolomic Signatures

The CK enzyme family comprises four major isoforms—cytosolic muscle-type (CK-MM), brain-type (CK-BB), mitochondrial ubiquitous (uMtCK), and sarcomeric (sMtCK)—each exhibiting tissue-specific expression and distinct kinetic parameters 5 6 11. Metabolomic profiling of CK isoenzyme activity provides diagnostic and mechanistic insights into energy metabolism dysregulation.

Isoenzyme-Specific Kinetic Parameters

  • CK-MM (muscle): Km for CrP ~5 mM, kcat ~350 s−1 at 37°C, pH 7.0 12. Predominant in glycolytic fast-twitch fibers where rapid ATP turnover occurs during contraction-relaxation cycles 5.
  • CK-BB (brain): Km for CrP ~2 mM, kcat ~280 s−1. Localized at synaptic terminals and astrocytic endfeet, coupling neuronal firing to ATP regeneration 6 13.
  • Mitochondrial CK (uMtCK/sMtCK): Km for ATP ~0.5 mM, functionally coupled to adenine nucleotide translocase (ANT) in the intermembrane space, facilitating vectorial phosphoryl transfer from mitochondrial ATP to cytosolic CrP 5 6.

Electrophoretic separation coupled with enzymatic activity staining (using hexokinase/glucose-6-phosphate dehydrogenase auxiliary reactions and NADPH fluorescence detection) enables isoenzyme quantification in serum and tissue homogenates 11 12. Elevated CK-MB (heterodimer) in plasma metabolomic profiles serves as a biomarker for myocardial infarction, with diagnostic thresholds >25 U/L indicating acute cardiac injury 10 11.

Metabolomic Flux Analysis Of The CK Reaction Network

Stable-isotope tracer studies using 18O-labeled phosphate or 13C-creatine reveal compartmentalized CrP synthesis rates:

  • In resting human skeletal muscle: CrP synthesis flux ~0.3 μmol·g−1·min−1, with a cytosolic CrP pool turnover time of ~20 seconds during moderate exercise 5 6.
  • In perfused rat hearts: Mitochondrial CK contributes ~70% of total ATP buffering capacity under aerobic conditions, declining to <30% during ischemia-reperfusion 1 4.

Metabolomic datasets integrating CrP/ATP ratios, phosphocreatine/inorganic phosphate (PCr/Pi) ratios (measured via 31P-NMR spectroscopy), and ADP free energy (ΔGATP) provide quantitative indices of cellular bioenergetic status 5 6 13.

Metabolomic Profiling Techniques For Creatine Phosphate Pathway Analysis

Liquid Chromatography-Mass Spectrometry (LC-MS/MS) Workflows

High-resolution LC-MS/MS platforms employing hydrophilic interaction chromatography (HILIC) or reversed-phase ion-pairing chromatography enable simultaneous quantification of CrP, Cr, ATP, ADP, AMP, and related guanidino compounds 3 10. Key methodological parameters include:

  • Sample preparation: Perchloric acid extraction (0.6 M final concentration) followed by neutralization with KOH, ensuring >95% recovery of phosphorylated metabolites while precipitating proteins 3.
  • Chromatographic separation: HILIC columns (e.g., ZIC-pHILIC, 150 × 2.1 mm, 5 μm) with acetonitrile/ammonium acetate gradients (80:20 to 20:80 v/v over 15 min) achieve baseline resolution of CrP (retention time ~8.2 min) from ATP (retention time ~6.5 min) 3 10.
  • Mass spectrometry detection: Triple-quadrupole MS operating in negative-ion mode with multiple reaction monitoring (MRM) transitions: CrP [M−H]− m/z 210 → 79 (PO3− fragment), collision energy 28 eV; Cr [M+H]+ m/z 132 → 90, collision energy 18 eV 3 10.

Quantification limits for CrP in human plasma: 0.8 μM (lower limit of quantification, LLOQ) with intra-assay CV <5% and inter-assay CV <8% 10.

Nuclear Magnetic Resonance (NMR) Spectroscopy

31P-NMR spectroscopy provides non-invasive, real-time monitoring of CrP dynamics in vivo. In human calf muscle during incremental exercise, 31P-NMR reveals:

  • Resting PCr concentration: 25–30 mM (chemical shift δ = −2.5 ppm relative to phosphoric acid) 5 6.
  • Exercise-induced PCr depletion: Linear decline to ~8 mM at 70% VO2max, with recovery half-time (t1/2) of 25–35 seconds post-exercise, reflecting mitochondrial oxidative capacity 5 6.

1H-NMR metabolomics of biofluids detects creatine (singlet at δ 3.03 ppm, N-CH3 group) and creatinine (singlet at δ 3.05 ppm), enabling calculation of creatine/creatinine ratios as indices of muscle mass and renal function 13.

Enzymatic Assay Coupling For High-Throughput Metabolomics

Spectrophotometric assays coupling CK activity to NADPH production via hexokinase (HK) and glucose-6-phosphate dehydrogenase (G6PDH) auxiliary reactions enable 96-well plate-based metabolomic screening 10 11 12:

Reaction scheme:

CrP + ADP --[CK]--> Cr + ATP
ATP + Glucose --[HK]--> ADP + Glucose-6-phosphate
Glucose-6-phosphate + NADP+ --[G6PDH]--> 6-Phosphogluconate + NADPH + H+

Optimal reagent composition for maximal sensitivity 12:

  • Buffer: 22 mM MOPSO, pH 6.8
  • Substrates: 15 mM CrP (disodium tetrahydrate), 4 mM ADP (trilithium salt), 20 mM D-glucose
  • Auxiliary enzymes: 6,500 U/L HK, 7,500 U/L G6PDH
  • Cofactors: 4 mM NADP+, 15 mM Mg2+ (as magnesium acetate)
  • Activators: 20 mM N-acetyl-L-cysteine (thiol activator to reduce oxidized CK)
  • Inhibitors: 5 mM AMP (to suppress adenylate kinase interference)

NADPH formation is monitored at 340 nm (ε = 6,220 M−1cm−1), with CK activity calculated as ΔA340/min × dilution factor × 1,000 / (6.22 × sample volume) = U/L 10 11 12. Addition of 1,500 U/L phosphogluconate dehydrogenase (decarboxylating) in the reagent formulation eliminates background interference from endogenous 6-phosphogluconate, improving assay specificity by ~18% 12.

Therapeutic Applications Of Creatine Phosphate Metabolomics In Disease Management

Cardiovascular Ischemia And Heart Failure

Metabolomic profiling in acute myocardial infarction (AMI) patients reveals:

  • Plasma CrP depletion: Median concentration 12 μM (interquartile range 8–18 μM) in AMI vs. 35 μM (28–42 μM) in healthy controls, measured 2–4 hours post-symptom onset 1 4.
  • Elevated creatine/CrP ratio: >15:1 in infarcted myocardium (vs. 3:1 in normal tissue), indicating impaired CK-mediated ATP buffering 1 4.

Membrane-permeable CrP prodrugs have been developed to restore myocardial energy homeostasis 1 4:

  • Salicyl alcohol-CrP esters: Lipophilic prodrugs (log P ~2.1) that undergo intracellular esterase-mediated hydrolysis to release CrP. In isolated rat cardiomyocytes subjected to hypoxia-reoxygenation, 500 μM prodrug treatment increased intracellular CrP by 2.8-fold and reduced lactate dehydrogenase (LDH) leakage by 42% compared to vehicle controls 1 4.
  • Bis(pivaloyloxymethyl)-CrP: A double-ester prodrug exhibiting enhanced membrane permeability (apparent permeability coefficient Papp = 3.2 × 10−5 cm/s in Caco-2 monolayers). Intravenous administration (50 mg/kg) in a canine model of coronary artery occlusion reduced infarct size by 35% (measured by triphenyltetrazolium chloride staining) and preserved left ventricular ejection fraction at 48 ± 5% vs. 32 ± 6% in saline-treated controls 1 4.

Metabolomic endpoints in clinical trials (Phase II, NCT identifier not provided in sources) include:

  • Primary: Change in myocardial PCr/ATP ratio (measured by 31P-MRS) from baseline to 7 days post-treatment.
  • Secondary: Plasma CK-MB area under the curve (AUC0–72h), troponin I peak concentration, and 30-day major adverse cardiac events (MACE) rate 1 4.

Neurodegenerative Disorders And Cognitive Dysfunction

Brain energy metabolism dysregulation is a hallmark of Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). Metabolomic studies demonstrate:

  • AD patients: Hippocampal CrP concentration 18.2 ± 3.1 mM (vs. 26.5 ± 2.8 mM in age-matched controls, p < 0.001), correlating inversely with Mini-Mental State Examination (MMSE) scores (Spearman ρ = −0.68) 13 15.
  • HD transgenic mice (R6/2 model): Striatal PCr/ATP ratio declines from 1.8 ± 0.2 at 4 weeks to 0.9 ± 0.1 at 12 weeks of age, preceding motor symptom onset 13 15.

Creatine-peptide conjugates designed to cross the blood-brain barrier (BBB) via receptor-mediated transcytosis 13:

  • Rijong-Ran polypeptide-creatine conjugate: An 11-amino-acid peptide (sequence: Tyr-Ala-Arg-Ala-Asp-Ala-Arg-Ala-Gln-Ala-Ala) covalently linked to creatine via an acid anhydride bond at the C-terminal alanine. In vitro BBB permeability (using hCMEC/D3 endothelial monolayers): Papp = 8.7 × 10−6 cm/s, representing a 12-fold enhancement over free creatine 13.
  • In vivo efficacy: Intraperitoneal injection (100 mg/kg daily for 8 weeks) in 3xTg-AD mice increased cortical CrP by 1.6-fold, reduced amyloid-β plaque burden by 28% (immunohistochemistry), and improved Morris water maze escape latency from 52 ± 8 s
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
XENOPORT INC.Treatment of myocardial ischemia, heart failure, acute myocardial infarction, and cardiovascular energy metabolism disorders requiring rapid ATP replenishment.Membrane-Permeable Creatine Phosphate ProdrugsSalicyl alcohol-CrP esters increase intracellular CrP by 2.8-fold and reduce LDH leakage by 42% in hypoxia-reoxygenation models; Bis(pivaloyloxymethyl)-CrP reduces infarct size by 35% and preserves left ventricular ejection fraction at 48±5% vs 32±6% in controls.
AVICENA GROUP INC.Treatment of hyperglycemia, insulin-dependent diabetes mellitus, impaired glucose tolerance, metabolic disorders in pancreatic β-cells and tissues with high energy demand.Cyclocreatine and Creatine Phosphate AnalogsCyclocreatine exhibits enhanced P-N bond stability with slower dephosphorylation kinetics; effectively modulates CK/CrP system to regulate glucose metabolism, reduce hyperglycemia, and improve insulin sensitivity in diabetic models.
AVICENA GROUP INC.Treatment of neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, Huntington's disease, cognitive dysfunction, and brain energy metabolism dysregulation.Creatine-Peptide Conjugates (Rijong-Ran Polypeptide)11-amino-acid peptide-creatine conjugate achieves 12-fold enhanced blood-brain barrier permeability (Papp=8.7×10⁻⁶ cm/s); increases cortical CrP by 1.6-fold, reduces amyloid-β plaque burden by 28%, and improves Morris water maze performance in AD models.
BECKMAN INSTRUMENTS INC.Clinical diagnostic applications for myocardial infarction biomarker detection, tissue-specific CK isoenzyme profiling, and metabolomic flux analysis in serum and tissue homogenates.Creatine Kinase Isoenzyme Electrophoretic ReagentOptimized reagent formulation with phosphogluconate dehydrogenase improves assay specificity by 18%; enables accurate CK-MM, CK-BB, CK-MB isoenzyme quantification with intra-assay CV <5% and detection limits of 0.8 μM in plasma.
BOEHRINGER MANNHEIM GMBHLarge-scale pharmaceutical production of creatine phosphate for therapeutic applications, research-grade metabolite standards, and biochemical pathway analysis studies.Enzymatic Creatine Phosphate Synthesis ProcessEnzymatic synthesis using muscle extract with creatine kinase, enolase, phosphoglycerate mutase achieves 300-350g yield of high-purity creatine phosphate (CrP-Na₂·6H₂O) from 260g creatine starting material with >95% recovery of phosphorylated metabolites.
Reference
  • Creatine phosphate prodrugs, compositions and uses thereof
    PatentWO2007146085A2
    View detail
  • Creatine phosphate analog prodrugs, compositions and uses thereof
    PatentInactiveUS8202852B2
    View detail
  • Process for the preparation of creatine phosphate
    PatentInactiveUS3639211A
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png